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Abstract
Oral insulin is an exciting area of research and development in the field of diabetology. This brief review covers the
various approaches used in the development of oral insulin, and highlights some of the recent data related to
novel oral insulin preparation.
Introduction
Insulin has saved the lives of countless people, since its
discovery in 1922. However, the difficulties associated
with subcutaneous administration, need for frequent self
monitoring of glucose, and non-physiological action
profiles of insulin prompted many physicians (and their
patients!) to ask for non-injectable methods of insulin
delivery.
The first oral insulin preparations were tried, with
poor results, by Joslin, in 1922 and 1923. Since then,
many researchers have worked on this concept, with no
success [1].
Currently, however, a few insulin molecules designed
for oral administration are in clinical trials, and promise
to reach clinical use soon. This review analyses the cur-
rent status of oral insulin. It focuses only on those pre-
parations which are actively being worked on, and does
not cover methodologies on which work has stopped.
Clinical data on this topic is relatively scarce, and this
explains the short length of the review.
The need for Oral Insulin
Resistance to injectable insulin has been identified as a
major reason for clinical inertia and lack of achievement
of target glycemic goals. Physicians as well as patients
fear the complexity of insulin regimes, the risk of hypo-
glycemia, and the chances of weight gain, as well as the
necessity of a needle prick, with insulin therapy. Insulin
is perceived to have a high index of intrusion as the con-
ventional insulins need to be given prior to meals [2].
Patients anticipate the early development of an oral
insulin, as it will be easy to administer, have a lower
index of intrusion, be more convenient, and have more
compliance or adherence from the patient, and finally
lead to better glycemic control, and thus, prevention of
complications of diabetes [3].
Oral insulin may improve b-cell function by providing
b-cell rest [4], and may help in preventing diabetes via
induction of ‘oral tolerance’ or immuno modulation [5,6].
Oral insulin is able to achieve a high porto-systemic
gradient, as it is delivered to the liver from the gastroin-
testinal tract. This reduces systemic insulin exposure
and may obviate the excessive weight gain sometimes
seen with subcutaneous insulin.
Oral insulin may also be able to correct the blunting
of first-phase release of insulin [7], which is difficult
with conventional subcutaneous insulins.
Barriers to oral insulin
The gastro intestinal tract has many physiological bar-
riers which prevent optimal delivery of oral insulin.
Physiological function of the gut enzymes is to break
large “active” proteins into smaller “inactive” amino
acids so that they can overcome the second absorption
barrier “tight epithelium” in the gastro intestinal tract.
These two essential barriers have been created by
Mother Nature to prevent body from potentially danger-
ous proteins. Researchers are trying to selectively break
this natural defence mechanism so that helpful large
“active protein” drugs can cross this barrier and produce
desired pharmacological effects.
Enzymes such as pepsin, trypsin, chymotrypsin, car-
boxypeptidase and pancreatin break proteins such as
insulin into amino acids with great efficiency [8].
The insulin that survives faces a barrier to absorption as
well. The intestine has tightly bound columnar cells with
hydrophobic proteins called occludins, and a thick layer of
mucin, which prevent absorption of insulin [9,10].* Correspondence: brideknl@gmail.com
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Further to these barriers the absorbed insulin has to
go through first pass metabolism at liver before reaching
at peripheral sites of action unlike sub-cutaneously
administered insulin which directly reaches peripheral
sites. This direct entry of insulin into liver has been pos-
tulated as being of physiological advantage by several
authors however long-terms effect of this are yet to be
seen [8,11].
Readers interested in more information on barriers to
oral insulin delivery are referred to more detail review
on the subject by Heinemann L and Jacques Y [3].
Approaches to oral insulin
Various workers have tried different approaches to over-
come the above mentioned barriers.
Insulin has been encapsulated in nanoparticles by
muco-adhesive polymers such as chitosan, poly (lactic-
co-glycolic acid) (PLGA), and alginate [12-17], which
prevent enzymatic degradation, and allow absorption
across the epithelial layer in Peyer’s patches [18]. This
approach depends on absorption of insulin in the colon,
which is too delayed to correct first phase insulin secre-
tion deficiency.
Insulin has also been co-administered with protease
inhibitors such as bacitracin, sodium glycocholate and
camostat mesilate [19], which improve the absorption
rate. However, the long-term effects of this approach
are not known.
Insulin can also be modified by PEGylation, or by add-
ing polyethylene glycol, which changes the pharmacoki-
netics, prevents enzymatic degradation, and increases
absorption [20].
Other workers have used permeation enhancers such as
fatty acid salts [21], Zonula occludens toxin (ZOT) [22],
and monosodium N-(4-chlorosalicyloyl)-4-aminobutyrate
(4-CNAB) [23]. These permeation enhancers may lead
to local inflammation and encourage gastro intestinal
infections.
Recent reports of oral insulin
An insulin analogue, IN-105, delivered orally in form of
tablets has been modified by linking a single short-
chain amphiphilic oligomer, through a covalent non-
hydrolysable amide bond, to the free amino acid group
on the Lys-b29 residue of recombinant human insulin.
This improves its solubility, stability and systemic
absorption [24]. Solubility is increased by PEGylation,
while stability may be due to steric hindrance.
IN-105 has similar insulin receptor binding and meta-
bolic activity similar to that of human insulin, while
exhibiting much lower (25-30%) insulin-like growth fac-
tor, receptor binding and mitogenic activity [24].
IN-105 has been studied in an open label, sequential
ascending dose, multicentric study in 20 subjects with
type 2 diabetes poorly controlled on stable metformin
monotherapy, to assess the dose requirement of the
molecule.
The average maximum fall in plasma glucose levels
was 18.1, 26.1, 29.0 and 30.8% after administration of
10, 15, 20 and 30 mg doses. The duration of fall of glu-
cose increased with increasing doses. Five subjects
experienced six mild episodes of hypoglycemia, all of
which occurred between 30 and 60 minutes of adminis-
tration of varying doses (15 to 30 mg) of IN-105. Other
adverse events were hypertriglyceridemia, dizziness and
hyperhydrosis. It appears that study demonstrated a
dose dependant decrease in post prandial glucose [24].
From the results published so far by the manufactures
it appears that IN-105 is rapid acting oral insulin which
could potentially find place in control of post prandial
hyperglycemia. Long term effects on HbA1c reduction
and beta cell function are yet to be seen. It is presently
being studied in a phase 3 trial in type 2 diabetes, as well
as a phase 1 trial in type 1 diabetes, and is perhaps in the
most advanced development stage of all oral insulin.
In a recently published study it appears that one of
the oral insulins under development did not appear to
show dose-response relationship and the induced meta-
bolic effect was very small. A single centre open label,
randomized, two period cross over, isoglycemic glucose
clamp study has been performed on 10 male insulin-
naïve patients with type 2 diabetes who received 300
units of oral insulin and 15 units of human regular insu-
lin on two separate days [23]. The oral insulin was com-
bined with 400 mg of a drug carrier molecule called
monosodium N-(4-chlorosalicyloyl)-4-aminobutyrate
(4-CNAB), which binds non covalently to insulin, and
improves gastro intestinal absorption [25,26].
Oral insulin led to early enhanced pharmacokinetic
and pharmacodynamic responses with a higher and fas-
ter peak of plasma insulin concentration as compared to
subcutaneous insulin. (Cmax 93 ± 71 vs. 33 ± 11 μU/ml,
and Tmax 27 ± 9 vs.161 ± 83 min) [23].
Bioavailability was 26 ± 28%, 7 ± 4%, and 2 ± 1% rela-
tive to subcutaneous insulin during 0-1 hour, 0-2 hours
and 0-6 hours. Biopotency was 55 ± 92%, 12 ± 9%, and
3 ± 1% for the same periods.
This proof-of-concept study has revealed the rapid and
short action of oral insulin, albeit with high variability,
and the efficacy of 4-CNAB as an absorption enhancer.
A similar randomized open label, cross over study has
been performed in 16 patients with type 2 diabetes, using
150 and 300 U oral insulin (Capsulin) and 12 IU regular
insulin. The hypoglycemic effect of 150 and 300 U of this
oral insulin was similar to each other, and was = 50% of
subcutaneous insulin [27,28]. This oral insulin is packaged
in an enteric coated capsule, which dissolves in the jeju-
num, and contains excepients that enhance its absorption.
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Another novel delivery mechanism is hepatic directed
vesicles (HDV-I) loaded with insulin, which are <150
nm diameter liposomes that contain insulin attached a
specific proprietary hepatocyte-targeting molecule
(HTM). HDV-1 is stable at low pH, in blood, is able to
avoid enzymatic degradation, and has high biopotency,
exhibited by its low dose of 5 U [3].
Studies have been performed in type 1 and type 2 dia-
betes [29], and a larger study is underway. Metabolic
control is much poorer with this oral insulin than with
subcutaneous insulin [29].
Another oral insulin in development for treatment of
type 1 and type 2 diabetes is ORMD-0801. The results
of a single-blind, open-label, single-center, Phase IIa
study in 8 T1DM, male subjects (ages 24-41, diabetics
for 2-28 years, HgA1C 6.63-8.63%), regularly treated
with no-peak insulin was recently presented. Two cap-
sules of ORMD-0801 (8 mg insulin each) were orally
administered to fasting subjects. A standard 400 kcal
meal was served at 10, 45 or 90 min thereafter. Blood
samples were collected over the 6-hr post insulin
administration to monitor insulin levels. Significant
increases in insulin levels were detected in 61% of the
treatment sessions (Tmax 40-180 min), irrespective of
timing of meals. In all cases, insulin levels returned to
baseline within 45-300 minutes of peak recordings,
demonstrating full clearance from the bloodstream.
Glucose Cmax was reached at an approximate 100-min
lag from start of meal (Range: 60-150 min), which in
17/23 cases returned to basal levels before the end of
the monitoring session. No serious adverse events were
recorded throughout the study. It appears that this
study showed some promise for control of post prandial
hyperglycemia in type 1 diabetes patients [30].
The company reported brief results in May 2010 of a
randomized, double-blind, placebo-controlled, multi-
centered 6-week study conducted in South Africa which
evaluated responses of 29 Type 2 diabetes patients to
ORMD-0801. The results stated a clinically relevant
reductions in insulin, c-peptide, fasting blood glucose
and Hb1Ac in the ORMD-0801 cohort, when compared
to the placebo. Also insulin and CRP levels were found
to be statistically significant; however complete results
are not yet out.
In a recent press release company developing
ORMD-0801 announced successful completion of a an
exploratory clinical trial testing the effectiveness of its
oral insulin capsule in Type 1 diabetes patients suffer-
ing from uncontrolled diabetes, however complete
results are not yet out [31].
Another oral insulin under development known as
NN1952 has recently completed Phase 1 studies with an
objective to study safety, tolerability, pharmacokinetics
and pharmacodynamics in healthy subjects and subjects
with type 1 and type 2 diabetes. This insulin has been
compared to placebo and insulin aspart injection. It will
be interesting to see the results of this study [23].
The Future of oral insulin
The physiological barriers to absorption of oral insulin,
its low bioavailability and low biopotency, and the high
inter-patient variability, are challenges that researchers
need to overcome before oral insulin can be considered
as suitable candidate for treatment of diabetes mellitus.
Recent reports, including proof-of-concept studies,
and early clinical studies, however, are reason for opti-
mism that oral insulin will soon become a reality.
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